Nano self-assembly of recombinant human gelatin conjugated with α-tocopheryl succinate for Hsp90 inhibitor, 17-AAG, delivery

ACS Nano

Volumn 5, Issue 5, 2011, Pages 3839-3848

  Won, Young Wook ^a   Yoon, Sun Mi ^a   Sonn, Chung Hee ^b   Lee, Kyung Mi ^b   Kim, Yong Hee ^a  

^a Hanyang University   (South Korea)

^b Korea University   (South Korea)

Author keywords

17 AAG; Alpha tocopheryl succinate; Anticancer drug delivery; Nanoparticles; Recombinant human gelatin; Self assembly

Indexed keywords

17-AAG; ALPHA-TOCOPHERYL SUCCINATE; ANIMAL IMAGING; ANTI-CANCER AGENTS; ANTI-CANCER DRUG DELIVERY; ANTICANCER DRUG; ANTICANCER EFFECTS; BIODEGRADABLE NANOPARTICLE; DEGRADING ENZYMES; DRUG DELIVERY SYSTEM; ENHANCED PERMEABILITY AND RETENTION EFFECT; HEAT SHOCK PROTEIN; HIGH MOLECULAR WEIGHT; IN-VIVO; LOADING EFFICIENCY; MOUSE MODELS; NATURAL BIOMATERIALS; PASSIVE TARGETING; RECOMBINANT HUMAN GELATIN; SELF-ASSEMBLED; SUSTAINED RELEASE; SYSTEMIC ADMINISTRATION; THERAPEUTIC EFFICACY; TUMOR AREAS; TUMOR MODELS;

BIOCOMPATIBILITY; BIOLOGICAL MATERIALS; DRUG DELIVERY; MAMMALS; SELF ASSEMBLY; TUMORS;

NANOPARTICLES;

17 ALDEHEDEYLOXY 19 GLUCOPYRANOSYLOXY LAB 8,13 DIEN 15 IOL; 17-ALDEHEDEYLOXY-19-GLUCOPYRANOSYLOXY-LAB-8,13-DIEN-15-IOL; ALPHA TOCOPHEROL; GELATIN; GLUCOSIDE; HEAT SHOCK PROTEIN 90; NANOCAPSULE; RECOMBINANT PROTEIN; TERPENE;

ANIMAL; ARTICLE; CHEMISTRY; DRUG ANTAGONISM; EXPERIMENTAL NEOPLASM; GENETICS; HUMAN; METABOLISM; MOUSE; PATHOLOGY;

ALPHA-TOCOPHEROL; ANIMALS; GELATIN; GLUCOSIDES; HSP90 HEAT-SHOCK PROTEINS; HUMANS; MICE; NANOCAPSULES; NEOPLASMS, EXPERIMENTAL; RECOMBINANT PROTEINS; TERPENES;

EID: 80051497797     PISSN: 19360851     EISSN: 1936086X     Source Type: Journal    
DOI: 10.1021/nn200173u     Document Type: Article

References (36)

1. Hwang, H.-Y.; Kim, I.-S.; Kwon, I. C.; Kim, Y.-H. Tumor Targetability and Antitumor Effect of Docetaxel-Loaded Hydrophobically Modified Glycol Chitosan Nanoparticles. J. Controlled Release 2008, 128, 23-31.
2. Li, L.; Tang, F.; Liu, H.; Liu, T.; Hao, N.; Chen, D.; Teng, X.; He, J. In Vivo Delivery of Silica Nanorattle Encapsulated Docetaxel for Liver Cancer Therapy with Low Toxicity and High Efficacy. ACS Nano 2010, 4, 6874-6882.
3. Du, Y.-Z.; Weng, Q.; Yuan, H.; Hu, F.-Q. Synthesis and Antitumor Activity of Stearate-G-Dextran Micelles for Intracellular Doxorubicin Delivery. ACS Nano 2010, 4, 6894-6902.
4. Won, Y.-W.; Kim, Y.-H. Recombinant Human Gelatin Nanoparticles as a Protein Drug Carrier. J. Controlled Release 2008, 127, 154-161.
5. Neuzil, J. Vitamin E Succinate and Cancer Treatment: A Vitamin E Prototype for Selective Antitumour Activity. Br. J. Cancer 2003, 89, 1822-1826. (Pubitemid 37533252)
6. Birringer, M.; EyTina, J. H.; Salvatore, B. A.; Neuzil, J. Vitamin E Analogues as Inducers of Apoptosis: Structure-Function Relation. Br. J. Cancer 2003, 88, 1948-1955. (Pubitemid 36829673)
7. Wang, X.-F.; Dong, L.; Zhao, Y.; Tomasetti, M.; Wu, K.; Neuzil, J. Vitamin E Analogues as Anticancer Agents: Lessons from Studies with A-Tocopheryl Succinate. Mol. Nutr. Food Res. 2006, 50, 675-685. (Pubitemid 44342464)
8. Kamal, A.; Boehm, M. F.; Burrows, F. J. Therapeutic and Diagnostic Implications of Hsp90 Activation. Trends Mol. Med. 2004, 10, 283-290. (Pubitemid 38725896)
9. Powers, M. V.; Workman, P. Inhibitors of the Heat Shock Response: Biology and Pharmacology. FEBS Lett. 2007, 581, 3758-3769. (Pubitemid 47081010)
10. Whitesell, L.; Lindquist, S. L. Hsp90 and the Chaperoning of Cancer. Nat. Rev. Cancer 2005, 5, 761-772. (Pubitemid 41400776)
11. Solit, D. B.; Chiosis, G. Development and Application of Hsp90 Inhibitors. Drug Discovery Today 2008, 13, 38-43.
12. Chiosis, G.; Neckers, L. Tumor Selectivity of Hsp90 Inhibitors: The Explanation Remains Elusive. ACS Chem. Biol. 2006, 1, 279-284.
13. Kamal, A.; Thao, L.; Sensintaffar, J.; Zhang, L.; Boehm, M. F.; Fritz, L. C.; Burrows, F. J. A High-Affinity Conformation of Hsp90 Confers Tumour Selectivity on Hsp90 Inhibitors. Nature 2003, 425, 407-410. (Pubitemid 37187270)
14. Li, Y.; Zhang, T.; Schwartz, S. J.; Sun, D. New Developments in Hsp90 Inhibitors as Anti-Cancer Therapeutics: Mechanisms, Clinical Perspective and More Potential. Drug Resist. Update 2009, 12, 17-27.
15. Workman, P.; Burrows, F.; Neckers, L E. N.; Rosen, N. Drugging the Cancer Chaperone Hsp90. Ann. N. Y. Acad. Sci. 2007, 1113, 202-216.
16. Roe, S. M.; Prodromou, C.; O'Brien, R.; Ladbury, J. E.; Piper, P. W.; Pearl, L H. Structural Basis for Inhibition of the Hsp90 Molecular Chaperone by the Antitumor Antibiotics Radicicol and Geldanamycin. J. Med. Chem. 1999, 42, 260-266. (Pubitemid 29069861)
17. Mimnaugh, E. G.; Chavany, C.; Neckers, L. Polyubiquitination and Proteasomal Degradation of the P185 (C-Erbb-2) Receptor Protein-Tyrosine Kinase Induced by Geldanamycin. J. Biol. Chem. 1996, 271, 22796-22801. (Pubitemid 26304727)
18. Neckers, L.; Schulte, T. W.; Mimnaugh, E. Geldanamycin as a Potential Anti-Cancer Agent: Its Molecular Target and Biochemical Activity. Invest. New Drugs 1999, 17, 361-373. (Pubitemid 30135903)
19. Heath, E.; Gaskins, M.; Pitot, H.; Pili, R.; Tan, W.; Marschke, R.; Liu, G.; Hillman, D.; Sarkar, F.; Sheng, S.; et al. A Phase II Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients with Hormone-Refractory Metastatic Prostate Cancer. Cl. Cllin. Genitourin. Cancer 2005, 4, 138-141. (Pubitemid 41474610)
20. Ronnen, E.; Kondagunta, G.; Ishill, N.; Sweeney, S.; DeLuca, J.; Schwartz, L.; Bacik, J.; Motzer, R. A Phase II Trial of 17-(Allylamino)-17- Demethoxygeldanamycin in Patients with Papillary and Clear Cell Renal Cell Carcinoma. In. Innvest. New Drugs 2006, 24, 543-546. (Pubitemid 44273031)
21. Zhang, H.; Neau, S. H. In Vitro Degradation of Chitosan by Bacterial Enzymes from Rat Cecal and Colonic Contents. Biomaterials 2002, 23, 2761-2766. (Pubitemid 34465735)
22. Wu, W.; Li, R.; Bian, X.; Zhu, Z.; Ding, D.; Li, X.; Jia, Z.; Jiang, X.; Hu, Y. Covalently Combining Carbon Nanotubes with Anticancer Agent: Preparation and Antitumor Activity. ACS Nano 2009, 3, 2740-2750.
23. Fox, M. E.; Szoka, F. C.; Frechet, J. M. J. Soluble Polymer Carriers for the Treatment of Cancer: The Importance of Molecular Architecture. Acc. Chem. Res. 2009, 42, 1141-1151.
24. Olsen, D.; Yang, C.; Bodo, M.; Chang, R.; Leigh, S.; Baez, J.; Carmichael, D.; Perälä, M.; Hämäläinen, E.-R.; Jarvinen, M.; et al. Recombinant Collagen and Gelatin for Drug Delivery. Adv. Drug Delivery Rev. 2003, 55, 1547-1567. (Pubitemid 37412593)
25. Cavalieri, F.; Postma, A.; Lee, L.; Caruso, F. Assembly and Functionalization of DNA-Polymer Microcapsules. ACS Nano 2009, 3, 234-240.
26. Zhou, H.; Yu, W.; Guo, X.; Liu, X.; Li, N.; Zhang, Y.; Ma, X. Synthesis and Characterization of Amphiphilic Glycidol-Chitosan-Deoxycholic Acid Nanoparticles as a Drug Carrier for Doxorubicin. Biomacromolecules 2010, 11, 3480-3486.
27. Dong, L. F.; Low, P.; Dyason, J. C.; Wang, X. F.; Prochazka, L.; Witting, P. K.; Freeman, R.; Swettenham, E.; Valis, K.; Liu, J. et al. [Alpha]-Tocopheryl Succinate Induces Apoptosis by Targeting Ubiquinone-Binding Sites in Mitochondrial Respiratory Complex II. On Onncogene. 2008, 27, 4324-4335. (Pubitemid 352010000)
28. Barzegar-Jalali, M.; Adibkia, K.; Valizadeh, H.; Shadbad, M.; Nokhodchi, A.; Omidi, Y.; Mohammadi, G.; Nezhadi, S.; Hasan, M. Kinetic Analysis of Drug Release from Nanoparticles. J. Pharm. Pharm. Sci. 2008, 11, 167-177.
29. Guo, W.; Reigan, P.; Siegel, D.; Zirrolli, J.; Gustafson, D.; Ross, D. Formation of 17-Allylamino-Demethoxygeldanamycin (17-Aag) Hydroquinone by Nad (P) H:Quinone Oxidoreductase 1: Role of 17-AAG Hydroquinone in Heat Shock Protein 90 Inhibition. Cancer Res. 2005, 65, 10006-10015. (Pubitemid 41541482)
30. Guo, W.; Siegel, D.; Ross, D. Stability of the Hsp90 Inhibitor 17AAG Hydroquinone and Prevention of Metal-Catalyzed Oxidation. J. Pharm. Sci. 2008, 97, 5147-5157.
31. Lee, S.-M.; Ahn, R. W.; Chen, F.; Fought, A. J.; O'Halloran, T. V.; Cryns, V. L.; Nguyen, S. T. Biological Evaluation of Ph-Responsive Polymer-Caged Nanobins for Breast Cancer Therapy. ACS Nano 2010, 4, 4971-4978.
32. Dempsey, G. T.; Bates, M.; Kowtoniuk, W. E.; Liu, D. R.; Tsien, R. Y.; Zhuang, X. Photoswitching Mechanism of Cyanine Dyes. J. Am. Chem. Soc. 2009, 131, 18192-18193.
33. Rosenthal, E. L.; Kulbersh, B. D.; King, T.; Chaudhuri, T. R.; Zinn, K. R. Use of Fluorescent Labeled Anti-Epidermal Growth Factor Receptor Antibody to Image Head and Neck Squamous Cell Carcinoma Xenografts. Mol. Cancer Ther. 2007, 6, 1230-1238. (Pubitemid 46711986)
34. Liang, X. J.; Chen, C.; Zhao, Y.; Jia, L.; Wang, P. C. Biopharmaceutics and Therapeutic Potential of Engineered Nanomaterials. Curr. Drug Metab. 2008, 9, 697-709.
35. Raulet, D. H.; Guerra, N. Oncogenic Stress Sensed by the Immune System: Role of Natural Killer Cell Receptors. Nat. Rev. Immunol. 2009, 9, 568-580.
36. Won, Y.-W.; Yoon, S.-M.; Lee, K.-M.; Kim, Y.-H. Poly (Oligo-D-Arginine) with Internal Disulfide Linkages as a Cytoplasm-Sensitive Carrier for siRNA Delivery. Mol. Ther. 2010, 19, 372-380.